Biotechnology Companies Face Scrutiny Over Incomplete Scientific Audit Trails

Biotechnology companies face mounting scrutiny over the reliability of their scientific records as researchers struggle to reconstruct key findings months after initial experiments.

A recurring problem involves laboratory reports that present conclusive data while failing to provide the underlying audit trails necessary to verify how those results were generated.

When a laboratory report lacks a clear connection to raw instrument files or metadata, the scientific conclusion becomes difficult to validate independently. This issue often surfaces when a reviewer attempts to trace a final measurement back to its origin, only to find that sample identifiers do not match across records or that the specific version of an analytical worksheet used remains unidentified.

The US Food and Drug Administration addressed these concerns in its December 2018 guidance on data integrity, which outlines how electronic records and metadata are essential to reconstruct activities in regulated drug manufacturing. While these specific requirements do not apply to every independent research project, the underlying principle of scientific accountability remains relevant for the broader biotechnology sector.

An effective audit trail documents the lifecycle of information, including any modifications, deletions, or changes to analytical values. Without such records, researchers and project managers struggle to tell a justified scientific correction from an unexplained change.

Metadata play a similarly critical role in ensuring data can be reused by others. Under the National Institutes of Health’s Data Management and Sharing Policy, which took effect on January 25, 2023, researchers are required to provide sufficient context for their datasets. Without metadata—such as measurement scales, methodologies, or transformations—numerical values often lose their scientific meaning, preventing other investigators from reliably interpreting or comparing results.

The integrity of these records directly impacts business operations. When a technical manager cannot confirm that a measurement corresponds to the correct sample or that the analytical procedure was appropriate, the organization may face delays while attempting to resolve the uncertainty. These gaps in documentation often require additional staff time and repeat testing to rectify.

The National Institutes of Health, founded in 1887 as a one-room Hygienic Laboratory within the Marine Hospital Service, became the primary federal agency for biomedical research.

By 2012 it comprised 27 separate institutes and centers, and its intramural program was the largest biomedical research institution in the world with 1,200 principal investigators and more than 4,000 postdoctoral fellows as of 2013. The NIH’s extramural arm provided 28% of annual U.S. biomedical research funding, about US$26.4 billion as of 2003, and its basic research contributed to every new drug approved by the FDA from 2010 to 2016.

In collaborative environments, the lack of version control further complicates research. When contributors work from different versions of an analytical file, they may unintentionally reach conflicting conclusions. Maintaining a transparent record of document versions is therefore necessary to ensure that all participants are relying on the same, validated information throughout the course of a project.

Photo of author

World Desk

World Desk at Archyde.

Grafana 13.3 Adds Shared Dashboard Variables, Notebooks in Public Preview